Pierre‐Yves Michellys
Genomics Institute of the Novartis Research Foundation · 77 works · 3,715 citations · h-index 24
Top works
- The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer
- Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
- Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials
- Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain
- Abstract B232: Activity of a potent and selective phase I ALK inhibitor LDK378 in naive and crizotinib-resistant preclinical tumor models.
- EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor
- Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex
- A Facile Cycloisomerization for the Formation of Medium and Large Rings via Allenes
- A Very Short Synthesis of Steroids from 1,3-Butadiene and Benzocyclobutenes
- Novel (2E,4E,6Z)-7-(2-Alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic Acid Retinoid X Receptor Modulators Are Active in Models of Type 2 Diabetes
- Regiochemistry of wacker-type oxidation of vinyl group in the presence of neighboring oxygen functions
- A five step synthesis of (d,l)-estrane derivatives from 1,3-butadiene
- NMR Structural Studies of Interactions of a Small, Nonpeptidyl Tpo Mimic with the Thrombopoietin Receptor Extracellular Juxtamembrane and Transmembrane Domains
- CYCLOADDITIONS OFortho-QUINODIMETHANES DERIVED FROM BENZOCYCLOBUTENES IN ORGANIC SYNTHESIS. A REVIEW
- Regiochemistry of Wacker-type oxidation of vinyl group in the presence of neighboring oxygen functions. Part 1
- Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers
- Biological Characterization of a Heterodimer-Selective Retinoid X Receptor Modulator: Potential Benefits for the Treatment of Type 2 Diabetes
- Regiochemistry of Wacker-type oxidation of vinyl group in the presence of neighboring oxygen functions. Part 2
- Design and synthesis of fluorinated RXR modulators
- Design, synthesis and structure–activity relationship of novel RXR-selective modulators